Product Description: Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT)[1].
Applications: Neuroscience-Neuromodulation
Formula: C28H34Cl2F2N2O
Citations: bioRxiv. 2024 Dec 23:2024.12.22.629999./Nature. 2024 Aug;632(8025):686-694./University of Groningen. 2016 Jun 1./Biochem Biophys Res Commun. 2020 May 14;525(4):989-996./Front Cell Neurosci. 2018 Sep 11;12:309. /Neuron. 2023 Mar 6;S0896-6273(23)00121-6.
References: [1]Rothman RB, et al. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol. 2008 Jan 1;75(1):2-16./[2]Andersen PH. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol./[3]Hirate K, et al. Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptakeinhibitor, in mice. Jpn J Pharmacol. 1991 Apr;55(4):501-11.
CAS Number: 67469-78-7
Molecular Weight: 523.49
Compound Purity: 99.60
Research Area: Neurological Disease
Solubility: DMSO : 9.4 mg/mL (ultrasonic;warming)/H2O : 1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Dopamine Transporter
Deutsch
English
